Boston Scientific’s CFO stands ground that buying troubled heart device maker Boston Scientific was the best thing the company ever did.
|
Medical device maker squirrels away the money to deal with the legal woes of Guidant.
|
Boston Scientific shares dip 7 percent after warnings some devices could cause problems.
|
Recent recalls stir discussion on the reporting and replacement of faulty cardiac devices.
|
Boston Scientific gets U.S. government clearance to acquire troubled heart device maker Guidant.
|
An independent panel suggests how the troubled heart device maker can better its patient safety communication skills.
|
Europe probes Boston-Guidant deal; Inamed’s outperforming wrinkle filler; polls shows Americans like techy medicine.
|
Inspectors say heart device maker failed to report in a timely manner on repair work for certain defibrillator products.
|
Boston Scientific and Guidant left Johnson & Johnson all alone by the telephone. So just who will J&J call?
|
The heart device maker's story takes a new twist as secret documents cause a stir.
|
Johnson & Johnson offers $24.2 billion for the heart device maker, still less than what rival suitor Boston Scientific has bid.
|
Medical product executive sold $3.39 million in stock days before Guidant began warning of product flaws.
|
Troubled medical device maker publishes report outlining the good and bad of the company’s product performance.
|
Device maker also reports Q3 net income dropped 60 percent.
|
A deadline passes without word from J&J on its $25.4-billion Guidant offer.
|
New York’s attorney general alleges Guidant concealed facts about its flawed defibrillator.
|
Pricey heart devices may actually be cost-effective when it comes to preventing heart attacks, says medical report.
|